

Literatur zum Artikel:

Chancen der kardiovaskulären Primärprävention

von Dr. med. Johannes Scholl

- [1] Häckl D, Weinhold I, Kossack N et al., Gutachten für den IKK e.V. zu Anreizen für Prävention im Morbi-RSA. WIG2 Wissenschaftliches Institut für Gesundheitsökonomie und Gesundheitssystemforschung. Leipzig 2016
- [2] Weinhold I et al., Economic impact of disease prevention in a morbidity based financing system: does prevention pay off for a statutory health insurance fund in Germany? European Journal of Health Economics 2019; 20: 1181–1193. <https://doi.org/10.1007/s10198-019-01086-7>
- [3] Kaplan H, Thompson RC, Trumble BC et al., Coronary atherosclerosis in indigenous South American Tsimane: a cross-sectional cohort study. Lancet 2017; 389(10080):1730–1739. doi: 10.1016/S0140-6736(17)30752-3.
- [4] Cao T, Cortez EC, Miyamoto MI et al., AHA 2023 Abstract 13719: Minimal and Delayed Age-Related Increase of Arterial Stiffness Among Tsimane Forager-Horticulturalists. Circulation 2023. https://doi.org/10.1161/circ.148.suppl_1.13719 Circulation. 2023; 148:A13719
- [5] Ference BA, Yoo W, Alesh I et al., Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012; 60(25): 2631–9. doi: 10.1016/j.jacc.2012.09.017.
- [6] Yusuf S, Hawken S, Ôunpuu S et al., Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study): case-control study. Lancet 2004; 364(9438): 937–952 doi: [https://doi.org/10.1016/S0140-6736\(04\)17018-9](https://doi.org/10.1016/S0140-6736(04)17018-9)
- [7] Subbotin V. Excessive intimal hyperplasia in human coronary arteries before intimal lipid depositions is the initiation of coronary atherosclerosis and constitutes a therapeutic target. Drug Discov Today 2016; 21(10): 1578–1595. doi: 10.1016/j.drudis.2016.05.017.
- [8] Chen W, Wang S, Lv W et al., Causal associations of insulin resistance with coronary artery disease and ischemic stroke: a Mendelian randomization analysis. BMJ Open Diabetes Res Care 2020; 8(1):e001217. doi: 10.1136/bmjdrc-2020-001217.
- [9] Sedding DG, Boyle EC, Demandt JA et al., Vasa Vasorum Angiogenesis: Key-Player in the Initiation and Progression of Atherosclerosis and Potential Target for the Treatment of Cardiovascular Disease. Front Immunol 2018; 9: 706. doi: 10.3389/fimmu.2018.00706.
- [10] Libby P. The changing landscape of atherosclerosis. Nature 2021; 592(7855): 524–533. doi: 10.1038/s41586-021-03392-8.
- [11] Neuman M, Bitton A, Glantz S, Tobacco industry strategies for influencing European Community tobacco advertising legislation. Lancet 2002; 359: 1323–30
- [12] Bornhäuser A, McCarthy J, Glantz SA: German tobacco industry's successful efforts to maintain scientific and political respectability to prevent regulation of secondhand smoke. https://www.dkfz.de/de/tabakkontrolle/download/Publikationen/German_Tobacco_Indust_Report_03_06.pdf
- [13] <https://www.tobaccocontrolscale.org/>, accessed 12.01.2024
- [14] <https://www.debra-study.info/>, accessed 12.01.2024
- [15] Yeh CY, Schafferer C, Lee JM et al., The effects of a rise in cigarette price on cigarette consumption, tobacco taxation revenues, and of smoking-related deaths in 28 EU countries – applying threshold regression modelling. BMC Public Health 2017; 17: 676. DOI 10.1186/s12889-017-4685-x
- [16] S3-Leitlinie "Rauchen und Tabakkabhängigkeit: Screening, Diagnostik und Behandlung". AWMF-Register Nr. 076–006. <https://register.awmf.org/de/leitlinien/detail/076-006>, accessed 12.01.2024
- [17] Näslund U, Ng N, Lundgren A et al., Visualization of asymptomatic atherosclerotic disease for optimum cardiovascular prevention (VIPVIZA): a pragmatic, open-label, randomised controlled trial. Lancet 2019; 393(10167): 133–142. doi: 10.1016/S0140-6736(18)32818-6.
- [18] Neuhauser H, Diederichs C, Boeing H et al., Hypertension in Germany – data from seven population-based epidemiological studies (1994–2012). Dtsch Arztebl Int 2016; 113: 809–15. DOI: 10.3238/arztebl.2016.0809
- [19] Wolf-Maier K, Cooper RS, Banegas JR, et al. Hypertension Prevalence and Blood Pressure Levels in 6 European Countries, Canada, and the United States. JAMA 2003; 289(18): 2363–2369. doi:10.1001/jama.289.18.2363
- [20] SPRINT Research Group. A Randomized Trial of Intensive versus Standard Blood-Pressure Control. N Engl J Med 2015;373(22): 2103–16. doi: 10.1056/NEJMoa1511939.

- [21] Williams B, Mancia G, Spiering W et al., 2018 ESC/ESH Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension: The Task Force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. *J Hypertens* 2018; 36(10): 1953–2041. doi: 10.1097/JHH.0000000000001940.
- [22] Unwin DJ, Tobin SJ, Murray SW et al., Substantial and Sustained Improvements in Blood Pressure, Weight and Lipid Profiles from a Carbohydrate Restricted Diet: An Observational Study of Insulin Resistant Patients in Primary Care. *Int J Environ Res Public Health* 2019; 16(15): 2680. doi: 10.3390/ijerph16152680.
- [23] Estruch R, Ross E, Salas-Salvadó J et al., Primary Prevention of Cardiovascular Disease with a Mediterranean Diet Supplemented with Extra-Virgin Olive Oil or Nuts. *N Engl J Med* 2018; 378:e34 DOI: 10.1056/NEJMoa1800389
- [24] Delgado-Lista J, Alcalá-Díaz JF, Torres-Peña JD et al., Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): a randomised controlled trial. *Lancet* 2022; 399(10338): 1876–1885. DOI:[https://doi.org/10.1016/S0140-6736\(22\)00122-2](https://doi.org/10.1016/S0140-6736(22)00122-2)
- [25] Ference BA, Graham I, Tokgozoglu L et al., Impact of Lipids on Cardiovascular Health: JACC Health Promotion Series. *J Am Coll Cardiol* 2018; 72(10): 1141–1156. doi: 10.1016/j.jacc.2018.06.046.
- [26] Tsimikas S, A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies. *J Am Coll Cardiol* 2017; 69(6): 692–711. doi: 10.1016/j.jacc.2016.11.042
- [27] Kronenberg F, Mora S, Stroes ESG et al., Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: A European Atherosclerosis Society Consensus Statement. *Eur Heart J* 2022; 43(39): 3925–3946. doi:10.1093/eurheartj/ehac361.
- [28] Giugliano RP, Pedersen TR, Park JG et al., Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. *Lancet* 2017; 390(10106):1962–1971. doi: 10.1016/S0140-6736(17)32290-0.
- [29] Tuomilehto J, Lindström J, Eriksson JG. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. *N Engl J Med* 2001; 344(18): 1343–50. doi: 10.1056/NEJM200105033441801.
- [30] Paulweber B et al. for the IMAGE Study Group. A European Evidence-Based Guideline for the Prevention of Type 2 Diabetes. *Horm Metab Res* 2010; 42(Suppl. 1): S3–S36. Doi: <http://dx.doi.org/10.1055/s-0029-1240928>
- [31] Unwin D, Delon C, Unwin J, et al. What predicts drug-free type 2 diabetes remission? Insights from an 8-year general practice service evaluation of a lower carbohydrate diet with weight loss. *BMJ Nutrition, Prevention & Health* 2023;0:e000544. doi:10.1136/bmjnph-2022-000544
- [32] American Diabetes Association. 5. Facilitating behavior change and wellbeing to improve health outcomes: Standards of Medical Care in Diabetes 2020. *Diabetes Care* 2020;43(Suppl. 1):S48–S65
- [33] Skurk T, Bosy-Westphal A, Grünerbel A et al., Empfehlungen zur Ernährung von Personen mit Typ-2-Diabetes mellitus. *Diabetologie* 2021; 16 (Suppl 2): S255–S289. DOI 10.1055/a-1543-1293
- [34] Atkinson FS, Brand-Miller JC, Foster-Powell K et al., International tables of glycemic index and glycemic load values 2021: a systematic review. *Am J Clin Nutr* 2021; 114(5): 1625–1632. doi: 10.1093/ajcn/nqab233.
- [35] Unwin D, Haslam D, Livesey G, It is the glycaemic response to, not the carbohydrate content of food that matters in diabetes and obesity: The glycaemic index revisited. *Journal of Insulin Resistance*. 2016;1(1), a8. <http://dx.doi.org/10.4102/jir.v1i1.8>
- [36] Taylor R, Barnes AC, Hollingsworth KG et al., Aetiology of Type 2 diabetes in people with a ‘normal’ body mass index: testing the personal fat threshold hypothesis. *Clinical Science* (2023) 137 1333–1346. Doi: <https://doi.org/10.1042/CS20230586>
- [37] WHO: Global status report on physical activity 2022, ISBN 978-92-4-005915-3 (electronic version). ISBN 978-92-4-005916-0 (print version)
- [38] Robert Koch-Institut, Gesundheitsmonitoring: Körperliche Aktivität. https://www.rki.de/DE/Content/Gesundheitsmonitoring/Themen/KoerperlAktivitaet/koerperl_aktiv_node.html, accessed 12.01.2024
- [39] Finger JD, Varnaccia G, Borrmann A et al., Körperliche Aktivität von Kindern und Jugendlichen in Deutschland – Querschnitteergebnisse aus KiGGS Welle2 und Trends. *Journal of Health Monitoring* 2018; 3(1): 24–31. DOI 10.17886/RKI-GBE-2018–006.2
- [40] Lumsden A, Mulugeta A, Zhou A et al., Apolipoprotein E (APOE) genotype-associated disease risks: a phenotype-wide, registry-based, case-control study utilising the UK Biobank. *Ebiomed* 2020; 59:102954. <https://doi.org/10.1016/j.ebiom.2020.102954>
- [41] Rasmussen JJ, Rasmussen KL, Nordestgaard BG et al., Impact of cardiovascular risk factors and genetics on 10-year absolute risk of dementia: risk charts for targeted prevention. *European Heart Journal* 2020; 41(41): 4024–4033, <https://doi.org/10.1093/eurheartj/ehaa695>

Literatur zum Artikel:

Rauchstopp jetzt

Vollständige Kostenübernahme für Tabakentwöhnung gefordert – eine Initiative der Hessischen Krebsgesellschaft e. V.

von Prof. Dr. rer. nat. Catharina Maulbecker-Armstrong, Prof. Dr. med. Christian Jackisch, Dr. med. Michael Weidenfeld, Karin Moser, Christina Benger, Prof. Dr. med. Stefan Andreas

- [1] Kotz D. DEBRA study – Deutsche Befragung zum Rauchverhalten; 2023+00:00 [Stand: 08.03.2024. 980Z]. Verfügbar unter: <https://www.debra-study.info/>. (DEBRA Studie, <https://www.debra-study.info/>)
- [2] Starker A, Kuhnert R, Hoebel J, Richter A. Rauchverhalten und Passivrauchbelastung Erwachsener – Ergebnisse aus GEDA 2019/2020-EHIS 2022. doi: 10.25646/10290.
- [3] Schalller K, Kahnert S, Graen L, Mons U, Ouédraogo N. Tabakatlas Deutschland 2020; 2020 [Stand: 08.03.2024]. Verfügbar unter: https://www.dkfz.de/de/tabakkontrolle/download/Publikationen/sonstVeroeffentlichungen/Tabakatlas-Deutschland-2020_dp.pdf.
- [4] WHO report on the global tobacco epidemic, 2019: Offer help to quit tobacco use. Geneva, Switzerland: World Health Organization; 2019.
- [5] Kurz C, Osterloh F. Prävention: Vorbeugen statt heilen; 2023 [Stand: 08.03.2024.629Z]. Verfügbar unter: <https://www.aerzteblatt.de/archiv/229938/Praevention-Vorbeugenstatt-heilen>.
- [6] Global Center for Good Governance in Tobacco Control. Global Tobacco Industry Interference Index 2023 [Stand: 08.03.2024.964Z]. Verfügbar unter: <https://globaltobaccoindex.org/>.
- [7] Joossens L, Olefir L, Feliu A, Fernandez E. The Tobacco Control Scale 2021 in Europe. Verfügbar unter: <https://www.tobaccocontrolscale.org/>.
- [8] Hanewinkel R, Hansen J. Konsum von Tabakzigaretten, E-Zigaretten und Wasserpfeifen bei Kindern und Jugendlichen. Ergebnisse des Präventionsradars von 2016 bis 2023. Pneumologie 2023; 77(12):1001–8. doi: 10.1055/a-2146-7087.
- [9] Ekpu VU, Brown AK. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence. Tob Use Insights 2015; 8:1–35. doi: 10.4137/tui.S15628.
- [10] Rauchen und Tabakabhängigkeit: Screening, Diagnostik und Behandlung [Stand: 08.03.2024]. Verfügbar unter: https://register.awmf.org/assets/guidelines/076-006l_S3_Rauchen_-Tabakabhaengigkeit-Screening-Diagnostik-Behandlung_2021-03.pdf.
- [11] Graen L, Schalller K. Strategie fuer ein tabakfreies Deutschland 2040 [Stand: 08.03.2024]. Verfügbar unter: https://www.dkfz.de/de/tabakkontrolle/download/Publikationen/sonstVeroeffentlichungen/2021_Strategie-fuer-ein-tabakfreies-Deutschland-2040_dp.pdf.
- [12] Hanewinkel R, Morgenstern M, Isensee B, Wiebel FJ. Rauchfreies Deutschland 2040: Ein Diskussionsbeitrag. Dtsch Med Wochenschr 2020; 145(18):e101-e107. doi: 10.1055/a-1162-3305.
- [13] U.S. Department of Health and Human Services. Smoking Cessation: A Report of the Surgeon General; 2020 [Stand: 08.03.2024.256Z]. Verfügbar unter: <https://www.cdc.gov/tobacco/sgr/2020-smoking-cessation/index.html>.
- [14] Andreas S, Rittmeyer A, Hinterthaler M, Huber RM. Smoking cessation in lung cancer-achievable and effective. Dtsch Arztebl Int 2013; 110(43):719–24. doi: 10.3238/ärztebl.2013.0719.
- [15] Reinhardt C, Harden M, Herrmann-Lingen C, Rittmeyer A, Andreas S. Smoking cessation by combined medication and counselling: a feasibility study in lung cancer patients. BMC Pulm Med 2022; 22(1):259. Verfügbar unter: <https://bmcpulmmed.biomedcentral.com/articles/10.1186/s12890-022-02048-1>.
- [16] Park ER, Perez GK, Regan S, Muzikansky A, Levy DE, Temel JS et al. Effect of Sustained Smoking Cessation Counseling and Provision of Medication vs Shorter-term Counseling and Medication Advice on Smoking Abstinence in Patients Recently Diagnosed With Cancer: A Randomized Clinical Trial. JAMA 2020; 324(14): 1406–18. Verfügbar unter: <https://pubmed.ncbi.nlm.nih.gov/33048154/>.
- [17] Raspe M, Bals R, Bölkbas S, Faber G, Krabbe B, Landmesser U et al. Tabakentwöhnung bei hospitalisierten Patienten:innen – Stationär einleiten,

- ambulant fortführen. Pneumologie 2023; 77(6):341–349. doi: 10.1055/a-2071–8900.
- [18] van Westen-Lagerweij NA, Hippel Walters BJ, Potyka F, Croes EA, Willemsen MC. Proactive Referral to Behavioral Smoking Cessation Programs by Healthcare Staff: A Systematic Review. Nicotine Tob Res 2023; 25(5):849–858. doi: 10.1093/ntr/ntac262.
- [19] Kastaun S, Leve V, Hildebrandt J, Funke C, Klosterhalfen S, Lubisch D et al. Training general practitioners in the ABC versus 5As method of delivering stop-smoking advice: a pragmatic, two-arm cluster randomised controlled trial. ERJ Open Res 2021; 7(3). doi: 10.1183/23120541.00621–2020.
- [20] van den Brand, F. A., Nagelhout GE, Reda AA, Winkens B, Evers, S. M. A.
- A., Kotz D et al. Healthcare financing systems for increasing the use of tobacco dependence treatment. Cochrane Database Syst Rev 2017; 9(9):CD004305. doi: 10.1002/14651858.CD004305.pub5.
- [21] Hanewinkel R. Gesundheitsrisiken der E-Zigarette. MMW Fortschr Med 2023; 165(3):62–63. doi: 10.1007/s15006–023–2

Literatur zum Artikel:

Medizinisch assistierter Suizid: Islamische Stellungnahmen im Kontext kultureller Vielfalt im Krankenhaus

Dr. phil. Martin Kellner

Kellner M (2019): Sterbehilfe im Koran? Ein Kommentar zur Handreichung „Sterbebegleitung und Palliative Care“ des Zentralrats der Muslime in Deutschland. In: Jahrbuch für interkultuelle Ethik im Gesundheitswesen Jg. 3 / 2019, S. 34–48.

Rosenthal F (1946) On Suicide in Islam. J Am Oriental Soc 66 (3):239–59
Schmacke, N. (2007): Palliativmedizin unter Betrachtung des demographischen Wandels: Was kann sich die Gesellschaft leisten? In: Medizinische Klinik, 102(7), S. 582–585.

Schulz D (2009) Dürfen Muslime sich selbst töten? Das Suizid-Verbot in der islamischen Theologie und dem islamischen Recht. Marburg: Tectum

Van den Branden, S., Broekaert, B. Living in the hands of God. English Sunni e-fatwas on (non-)voluntary euthanasia and assisted suicide. Med Health Care and Philos 14, 29–41 (2011).